<DOC>
	<DOCNO>NCT02471560</DOCNO>
	<brief_summary>The primary objective study determine dimethyl fumarate ( DMF ) cause change abundance diversity commensal microbiota . The secondary objective study follow : To identify difference gut microbiota composition patient develop gastro intestinal ( GI ) adverse event ( AEs ) , pre- post DMF treatment examine resolution GI AEs DMF treat patient reflect gut microbiota .</brief_summary>
	<brief_title>Tecfidera Gut Microbiota</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Have confirm diagnosis RRMS satisfy therapeutic indication describe local label . Female subject childbearing potential surgically sterile must practice effective contraception accord summary product characteristic ( SPC ) participation study willing able continue contraception 30 day last dose study treatment . Key Diagnosis primary progressive , secondary progressive progressive relapse MS . Antibiotic treatment last month prior study entry . Scheduled alteration diet , include use probiotic . NOTE : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Microbiota</keyword>
	<keyword>DMF</keyword>
	<keyword>Gastro intestinal</keyword>
	<keyword>MS</keyword>
</DOC>